01 influenza Loehr 508

CDC ACIP — Vaccine Advisory Committee

Acip

Slides

7

Document text

National Center for Immunization & Respiratory Diseases
Influenza Work Group —Introduction
Dr. Jamie Loehr (Work Group Chair)
Advisory Committee on Immunization Practices
October 25, 2023
Influenza Work Group
ACIP Members
•Jamie Loehr (Chair)
•Keipp Talbot 
•Camille Kotton
Ex Officio
•Timothy Brennan (FDA)
•Uzo Chukwuma (IHS)
•Jeffrey Kelman (CMS)
•Valerie Marshall (OASH)
•Cynthia Nolletti (FDA)
•Chris Roberts (NIH)Liaison Representatives and Consultants
•Robert Atmar
•Kevin Ault
•Ed Belongia
•Hank Bernstein
•Thomas Boyce
•Kris Bryant
•Doug Campos -Outcalt
•Sarah Coles
•Frances Ferguson
•Alicia Fry
•Sandra Fryhofer
•Wendy Keitel
•Marie -Michèle Léger
•Susan Lett
•Krissy Moehling•Zackary Moore
•Rebecca Morgan
•Kathy Neuzil
•Jesse Papenburg
•William Schaffner
•Rob Schechter 
•Ken Schmader 
•Tamara Sheffield
•Angela Sinilaite
•Patsy Stinchfield 
•Peter Szilagyi
•Matthew Zahn
CDC Lead
•Lisa Grohskopf
2
CDC Participants
•Lenee Blanton
•Karen Broder
•Alicia Budd
•Jessie Chung
•Sascha Ellington
•Jill Ferdinands
•Brendan Flannery
•Andrew Kroger
•Samantha Olson
•David Shay
•Tom Shimabukuro
•Mark Tenforde
•Tim Uyeki
3
Influenza Vaccines in Pregnancy
Updates:
• Safety of Quadrivalent Recombinant Influenza Vaccine in Pregnant Women and their Infants —
Dr. Nicky Klein (Kaiser Permanente Northern California)
• Pregnancy Outcomes with ccIIV4 (Flucelvax); Post Marketing Study —Dr. Gregg Sylvester (Seqirus)
• Effectiveness of Maternal Influenza Vaccination during Pregnancy Against Influenza -associated 
Hospitalizations & ED Visits in Infants <6 Months of Age— Ms. Samantha Olson (CDC/NCIRD)       
⁻ To be presented tomorrowIssues:
• Influenza vaccination recommended for pregnant persons
• While there is considerable experience with safe administration of influenza vaccines in 
pregnancy, there are fewer data specific to newer influenza vaccine formulations
4
Co-administration of Vaccines in Adults
Updates:
• Safety of Simultaneous versus Sequential Administration of mRNA COVID -19 and Quadrivalent 
Inactivated Influenza (IIV4) Vaccines —Dr. Emmanuel “Chip” Walter (Duke University)
• Safety of Simultaneous Vaccination with Zoster Vaccine Recombinant (RZV) and Quadrivalent 
Adjuvanted Inactivated Influenza Vaccine (allV4) —Dr. Kenneth Schmader (Duke University)
• Update on COVID -19 and Influenza Vaccine Safety —Dr. Tom Shimabukuro (CDC/NCIRD)Issues:
• Simultaneous administration or co -administration of all vaccines for which a recipient is due is a 
generally recommended practice for most combinations of vaccines
• Specific data for co -administration of many combinations involving newer vaccines are limited
• Data on co -administration of two or more vaccines with newer adjuvants are limited
5
Influenza B/Yamagata Surveillance
Update:
• Update on Influenza B/Yamagata Surveillance— Dr. Rebecca Kondor (CDC/NCIRD) 
⁻ To be presented tomorrowIssues:
• All current U.S. influenza vaccines are quadrivalent —they contain antigen from 4 influenza 
viruses, including an A(H1N1) virus, an A(H3N2) virus, and  2 influenza B viruses (one from each 
of two B lineages)
• Quadrivalent influenza vaccines were initially introduced in 2013- 14, to permit broader coverage 
of potentially circulating influenza B viruses (previous trivalent vaccines contained one influenza 
B virus from one lineage)
• There have been noconfirmed detections ofinfluenza B/Yamagata lineage viruses in global 
surveillance since March 2020, leading to discussion by WHO and FDA of their continued 
inclusion in influenza vaccines
6
For more information, contact CDC
1-800- CDC- INFO (232- 4636)
TTY:  1 -888- 232- 6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.